Trevi Therapeutics Announces Fourth Quarter and Year End 2020 Financial Results and Business Updates
March 25, 2021 16:05 ET
|
Trevi Therapeutics
Expects to Complete Enrollment and Report Top-Line Data of the Phase 2b/3 PRISM Trial in Second Half of 2021 Cash Position Expected to Fund Operations into the Second Quarter of 2022 NEW...
Trevi Therapeutics Appoints William Forbes, Pharm.D. as Chief Development Officer
February 01, 2021 07:30 ET
|
Trevi Therapeutics
Industry Veteran to Lead the Clinical Development of Haduvio™ in Multiple Indications NEW HAVEN, Conn., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage...
Trevi Therapeutics Announces Third Quarter 2020 Financial Results and Business Update
November 11, 2020 16:05 ET
|
Trevi Therapeutics
PRISM Trial of Haduvio™ for Severe Pruritus in Patients with Prurigo Nodularis Exceeds Halfway Enrollment Milestone Phase 2 Chronic Cough Trial in Patients with IPF Enrolled First New Subject...
Trevi Therapeutics to Present at Stifel Healthcare Conference
November 10, 2020 07:30 ET
|
Trevi Therapeutics
NEW HAVEN, Conn., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™...
Trevi Therapeutics to Report Q3 2020 Financial Results on November 11
November 04, 2020 16:05 ET
|
Trevi Therapeutics
NEW HAVEN, Conn., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™...
Trevi Therapeutics Provides Clinical Trial Updates for Haduvio™
October 21, 2020 08:00 ET
|
Trevi Therapeutics
Restart of Phase 2 Clinical Trial of Haduvio for Chronic Cough in Patients with IPF Phase 2b/3 PRISM Trial of Haduvio for Severe Pruritus in Patients with Prurigo Nodularis Reaches 50% Enrollment...
Trevi Therapeutics Announces the Hiring of Key Talent
October 13, 2020 16:05 ET
|
Trevi Therapeutics
NEW HAVEN, Conn., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™...
Trevi Therapeutics to Present at H.C. Wainwright Global Investment Conference
September 09, 2020 16:05 ET
|
Trevi Therapeutics
NEW HAVEN, Conn., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™...
Trevi Therapeutics Announces Second Quarter 2020 Financial Results and Business Update
August 13, 2020 16:05 ET
|
Trevi Therapeutics
Announced Positive Outcome of Sample Size Re-Estimation Analysis for PRISM Trial Strong Enrollment in PRISM Trial After Lifting of COVID-19 Restrictions Announces $14 Million Term Loan - Cash...
Trevi Therapeutics to Report Q2 2020 Financial Results on August 13
August 06, 2020 16:05 ET
|
Trevi Therapeutics
NEW HAVEN, Conn., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™...